Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80192
Name relapsed/refractory diffuse large B-cell lymphoma
Definition A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03340766 Phase I Blinatumomab + Pembrolizumab Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348) Active, not recruiting USA | FRA | ESP | DEU 2
NCT03401853 Phase II Pembrolizumab + Rituximab Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT03533283 Phase I Obinutuzumab + RO7082859 Obinutuzumab + Polatuzumab vedotin-piiq + RO7082859 + Tocilizumab Atezolizumab + Obinutuzumab + RO7082859 + Tocilizumab An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting USA | ITA | ESP | BEL 3
NCT03579927 Phase Ib/II Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Withdrawn USA 0
NCT03642626 Phase II Cyclophosphamide + Fludarabine + Tisagenlecleucel axicabtagene ciloleucel + Cyclophosphamide + Fludarabine MT2017-45: CAR-T Cell Therapy for Heme Malignancies Recruiting USA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN 1
NCT03684694 Phase I Ibrutinib + Loncastuximab tesirine-lpyl Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Active, not recruiting USA | ITA | FRA | ESP | BEL 1
NCT03688152 Phase I INCB053914 + Parsaclisib A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma Completed USA 0
NCT03736616 Phase II Acalabrutinib Carmustine + Cytarabine + Etoposide + Melphalan Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL Recruiting USA 0
NCT03798314 Phase I Nivolumab + Pomalidomide Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma Completed USA 0
NCT04156828 Phase I Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Recruiting USA 0
NCT04220008 Phase II Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT04285268 Phase II Bortezomib + Rituximab + Venetoclax Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Withdrawn USA 0
NCT04416984 Phase Ib/II ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2) Recruiting USA 0
NCT04502394 Phase Ib/II Acalabrutinib + KRT-232 Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL Recruiting USA | ITA | FRA | BEL 7
NCT04855253 Phase Ib/II E7777 Study of E7777 Prior to Kymriah for R/R DLBCL Recruiting USA 0
NCT04906096 Phase II GDC-0084 Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL Recruiting USA 0